Syndax Pharmaceuticals, Inc. (SNDX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $350.00M; Debt, CurrentUSD $344.03M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $350.00M; Debt, CurrentUSD $343.96M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $350.00M; Debt, CurrentUSD $343.91M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $327.07M; Debt, CurrentUSD $343.91M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
Syndax Pharmaceuticals, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Debt, Current USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $350.00M | $344.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $350.00M | $343.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $350.00M | $343.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $327.07M | $343.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $330.56M | $343.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $335.85M | $343.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $337.88M | $343.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $14.77M | $5.24M | (m) | (m) | $0.00 | $20.00M | (m) |
| 2022-03-31 | (m) | (m) | $14.77M | $5.24M | (m) | (m) | (m) | $20.00M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $14.76M | $5.24M | (m) | (m) | $20.00M | (m) |
| 2021-09-30 | (m) | (m) | $9.73M | $7.99M | (m) | (m) | $2.29M | $20.00M | (m) |
| 2021-06-30 | (m) | (m) | $9.73M | $7.99M | (m) | (m) | $2.29M | $20.00M | (m) |
| 2021-03-31 | (m) | (m) | $9.73M | $7.99M | (m) | (m) | $2.29M | $20.00M | (m) |
| 2020-12-31 | (m) | (m) | $2.29M | $9.73M | $7.99M | (m) | (m) | $20.00M | (m) |
| 2020-09-30 | (m) | (m) | $2.29M | $9.73M | $7.99M | (m) | (m) | $20.00M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $3.06M | $9.81M | $7.13M | (m) | $20.00M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $3.06M | $9.81M | $7.13M | (m) | $20.00M | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $5.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |